Adam replied to me on the Street with MORE goofy claims.......This is my reply.
You are seriously fact challenged to suggest index funds are behind heavy ownership of a $300 million market cap biotech. Market weighting makes that idea laughable, as are many of your columns. Fidelity, Federated, T-Rowe, Airel, Litespeed are not index funds.The suggestion that adverse events are needed to show efficacy is shot down by the TransVax success off the same platform for bone marrow or organ transplant recipients with obliterated immune systems. Moreover, if an immunotherapy can work with these most delicate of patients, how is it that it won't work for chemonaive cancer patients?